BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10

• Press Releases

  Landmark Data from Rutgers Cancer Institute and RWJBarnabas Health Show Long-term Complete Responses of T Cell Therapies for HPV-Related Cancers

  November 10, 2025

   · 

  7 min read
• Press Releases

  OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines

  November 10, 2025

   · 

  5 min read
• Press Releases

  Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74

  November 10, 2025

   · 

  7 min read
• Press Releases

  Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025

  November 10, 2025

   · 

  5 min read
• Press Releases

  CrossBridge Bio Wins “Best Drug Developer” at 2025 World ADC Awards

  November 10, 2025

   · 

  2 min read
• Press Releases

  Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

  November 10, 2025

   · 

  11 min read
• Press Releases

  Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

  November 10, 2025

   · 

  14 min read
• Press Releases

  A2 Biotherapeutics Presents Initial Safety and Efficacy Data from Ongoing Phase 1/2 EVEREST-2 Study, Including First Report of a Complete Response to CAR T-Cell Therapy in a Patient with NSCLC

  November 10, 2025

   · 

  8 min read
• Press Releases

  Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

  November 10, 2025

   · 

  8 min read
• Press Releases

  Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

  November 10, 2025

   · 

  4 min read